Cationic lipid-based nanoparticles mediate functional delivery of acetate to tumor cells in vivo leading to significant anticancer effects.
Loading...
Embargo End Date
ICR Authors
Authors
Brody, LP
Sahuri-Arisoylu, M
Parkinson, JR
Parkes, HG
So, PW
Hajji, N
Thomas, EL
Frost, GS
Miller, AD
Bell, JD
Sahuri-Arisoylu, M
Parkinson, JR
Parkes, HG
So, PW
Hajji, N
Thomas, EL
Frost, GS
Miller, AD
Bell, JD
Document Type
Journal Article
Date
2017-01-01
Date Accepted
Abstract
Metabolic reengineering using nanoparticle delivery represents an innovative therapeutic approach to normalizing the deregulation of cellular metabolism underlying many diseases, including cancer. Here, we demonstrated a unique and novel application to the treatment of malignancy using a short-chain fatty acid (SCFA)-encapsulated lipid-based delivery system - liposome-encapsulated acetate nanoparticles for cancer applications (LITA-CAN). We assessed chronic in vivo administration of our nanoparticle in three separate murine models of colorectal cancer. We demonstrated a substantial reduction in tumor growth in the xenograft model of colorectal cancer cell lines HT-29, HCT-116 p53+/+ and HCT-116 p53-/-. Nanoparticle-induced reductions in histone deacetylase gene expression indicated a potential mechanism for these anti-proliferative effects. Together, these results indicated that LITA-CAN could be used as an effective direct or adjunct therapy to treat malignant transformation in vivo.
Citation
International journal of nanomedicine, 2017, 12 pp. 6677 - 6685
Source Title
Publisher
DOVE MEDICAL PRESS LTD
ISSN
1176-9114
eISSN
1178-2013
Collections
Research Team
Magnetic Resonance